Chylothorax, Lymphatic Diseases
Conditions
Brief summary
This study aims to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. To study the effects of octreotide, the researchers conducted a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and other lymphatic disorders.
Detailed description
This study aimed to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. Chylothorax is a condition in which there is an accumulation of lymphatic fluid in the chest cavity, and the mechanism through which octreotide helps to resolve this condition is not well understood. It has been speculated that the drug may reduce lymph production, but this has not been directly demonstrated. To study the effects of octreotide on human lymphatic vessels, the investigators conducted two experiments: a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber, and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults, assessed by using plethysmography and near-infrared fluorescence imaging. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and to clarify the mechanism through which it acts. It is important to continue researching and developing effective treatments for chylothorax, as it can be a difficult condition to manage and may cause serious complications if left untreated.
Interventions
Octreotide infusion for 2,5 hours. 300 ng/kg/min bolus was given for the first 15 minutes and then a continuous infusion of 100 ng/kg/min for the remaining 135 minutes.
Saline Infusion
Sponsors
Study design
Masking description
Neither the participant nor investigator nor outcomes assessor was aware of whether saline or octreotide was infused on the day of investigation and data analysis.
Intervention model description
Double-blinded cross over study
Eligibility
Inclusion criteria
\* Healthy
Exclusion criteria
* No daily medication (except birth control), or allergies towards contrast agents.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lymph rate | During infusion | Propulsions /minute |
| Lymph Pressure | During infusion | mmHg assessed by near-infra fluorescence imaging |
| Capillary filtration rate | During infusion | assessed by plethysmography |
| Capillary filtration coefficiency | During infusion | assessed by plethysmography |
| Isovolumetric pressure | During infusion | assessed by plethysmography |
Countries
Denmark